Abstract: Several peripheral blood mononuclear cell (PBMC)-derived cell populations can promote angiogenesis, and differences in CD34+ or CD14+ surface-expression have been used to separate PBMCsubpopulations in this respect. AngiomiRs, microRNAs regulating angiogenesis, have been identified as key regulators of angiogenic processes. The present study examines differential angiomiR-expression/secretion from CD34+/CD14+; CD34+/CD14-; CD34-/CD14+; CD34-/CD14-PBMC-subsets and their relevance for different pro-angiogenic properties. Notably, both circulating human CD34+/14+ and CD34+/14-PBMC-subsets and their supernatants exerted more potent pro-angiogenic effects as compared to CD34-PBMC-subsets. MiR-126 was identified as most differentially expressed angiomiR in CD34+ as compared to CD34-PBMC-subsets, determined by miR-array and RT-PCR validation. Modulation of miR-126 by anti-miR-126 or miR-mimic-126 treatment resulted in significant loss or increase of pro-angiogenic effects of CD34+PBMCs. MiR-126 levels in supernatants of CD34+PBMC-subsets were substantially higher as compared to CD34-PBMC-subsets. MiR-126 was secreted in microvesicles/exosomes, and inhibition of their release impaired CD34+PBMCs pro-angiogenic effects. Notably, high-glucose treatment or diabetes reduced miR-126-levels of CD34+PBMCs, associated with impaired pro-angiogenic properties that could be rescued by miR-mimic-126 treatment. The present findings provide a novel molecular mechanism underlying increased pro-angiogenic effects of CD34+PBMC-subpopulations, i.e. angiomiR-126 expression/secretion. Moreover, an alteration of angiomiR-126-expression in CD34+PBMC in diabetes provides a new pathway causing impaired pro-angiogenic effects. The present findings provide a novel molecular mechanism underlying increased pro-angiogenic effects of CD34+PBMC-subpopulations, i.e. angiomiR-126 expression/secretion. Moreover, an alteration of angiomiR-126-expression in CD34+PBMC in diabetes provides a new pathway causing impaired pro-angiogenic effects.
to promote angiogenesis and differences in both, CD34+ or CD14+ surface expression, have been used to separate functionally different PBMC sub-populations in this respect [1] [2] [3] [4] [5] . In particular, human CD34+ PBMC have been shown to promote angiogenesis in response to ischemia 1, 3, 5 , resulting largely from paracrine effects. Administration of CD34+ PBMCs is also being evaluated as a potential treatment of ischemic heart disease and limb ischemia 6, 7 .
However, an impaired cardiovascular repair function of autologous patient-derived progenitor cells, in particular a reduced capacity to promote neo-vascularization, has been suggested in diabetes and ischemic heart disease [8] [9] [10] [11] [12] , that may limit the efficacy of cell-based therapies in these patients and the underlying mechanisms need to be fully elucidated.
Moreover, PBMCs have been suggested as a source of both, early and late outgrowth "endothelial progenitor cells" 2 and differences in CD14+ expression have been proposed to distinguish mononuclear cells representing a source of early or late outgrowth cells in this respect 13 . The vast majority of early "endothelial progenitor cells" has been suggested to arise from CD14+ subpopulations of PBMCs, whereas late outgrowth "endothelial progenitor cells" with a potential for differentiation towards endothelial cells were reported to be derived from CD14-mononuclear cell fractions 2, 13 .
Importantly, several microRNAs (miRs) have recently been identified as critical regulators of vascular development and angiogenesis that have been termed angiomiRs [14] [15] [16] [17] . Moreover detection of circulating miRs in serum/plasma as well as secretion of miRs or their release in apoptotic micro-particles has recently been reported, suggesting that miRs may also play a regulatory role outside of the cell and thereby impact on target cells [18] [19] [20] [21] [22] The present study was therefore designed to determine whether there is differential angiomiR expression of these different PBMC subsets, separated for CD34+ expression as well as CD14+ surface expression, i.e. CD34+CD14+ and CD34+14-as well CD34-/14+ and CD34-14-PBMC subpopulations. Furthermore, we aimed to examine the potential role of differential angiomiR expression for differences in the pro-angiogenic capacity. In addition, the impact of highglucose or type-2 diabetes on angiomiR expression and its relevance for the altered proangiogenic effects was examined.
Materials and Methods
Cell Isolation: PBMCs from healthy male volunteers (age: 49±4 years) were isolated from buffy coats by density-gradient centrifugation, washed twice in phosphate-buffered saline (PBS) containing 2 mM EDTA and 0.5% serum albumin. MNCs (~ 500x 10 6 ) were split, i.e. half of the PBMCs were incubated with anti-CD14 micro-beads (Miltenyi Biotec) for 30min., and separated through a column of a MACS separator (Miltenyi Biotec Diabetes was induced with streptozotocin in as described previously 26 . After 3 weeks of diabetes the animals were used for the experiments.
CD34+ Cell Isolation from Diabetic Patients:
Written informed consent was obtained from all patients and healthy subjects, and the study protocol was approved by the local ethics committee. CD34+ PBMCs were also isolated from patients with type-2 diabetes and agematched healthy subjects to compare the microRNA expression levels (57±3 vs. 53±5 years;
P=n.s.).
In-vivo Angiogenesis assays:
PBMC sub-fractions: In-vivo matrigel plug assay was performed as described previously 27 between groups were analysed using one-way ANOVA, followed by Bonferroni post-hoc test. A value of P<0.05 was considered to be statistically significant.
Results

Both CD34+CD14+ and CD34+CD14-PBMC subsets exhibit a substantially greater proangiogenic capacity as compared to CD34-/CD14+ and CD34-/CD14-MNC subsets in-vitro and in-vivo
Tube formation capacity was compared for two CD34+ PBMC subsets (CD34+CD14+ and CD34+CD14-) and two CD34-cell PBMC subsets (CD34-CD14+ and CD34-CD14-) isolated from circulating PBMCs. Both CD34+ cell fractions had a substantially higher pro-angiogenic capacity as indicated by an increased tube formation capacity in HAEC-co-culture assay, as compared to CD34-CD14+ and CD34-CD14-PBMC fractions (Fig.1A,B ). Since CD34+ PBMCs have been suggested to promote angiogenesis largely via paracrine mechanisms, conditioned medium from the CD34+ and CD34-PBMC fractions was assessed. Supernatants from CD34+
PBMC fractions had a higher stimulatory capacity for tube formation as compared to CD34-PBMC-fraction supernatants. No significant difference was observed between CD34+CD14+
and CD34+CD14-PBMC supernatants (Fig.1C ). The analysis of the pro-angiogenic capacity invivo, in line with the above results, suggested a higher pro-angiogenic stimulatory capacity of both CD34+ PBMC fractions as compared to CD34-PBMC fractions (Fig.1D) . Furthermore, we observed a more pronounced effect of CD34+ cells on angiogenesis in-vivo using the matrigel plugs with an increasing CD34+ cell number (Suppl. Fig. 3A ).
Increased angiomiR miR-126 expression in CD34+ as compared to CD34-PBMC subsets
To investigate potential novel mechanisms explaining different pro-angiogenic effects in CD34+
and CD34-PBMC subpopulations, angiomiR expression patterns were assessed in the above cell populations. Human Cell Differentiation & Development RT PCR array was performed using total RNA isolated from CD34+CD14+, CD34+ CD14-, CD34-CD14+, CD34-CD14-cell fractions. Within the 8 most expressed miRs of the microRNA array we identified the angiomiR miR-126 ( Fig.2A i-viii) . Moreover, the miR-126 was identified as the angiomiR that was most profoundly higher expressed in CD34+ as compared to CD34-MNC sub-fractions ( Fig.2B i-viii) .
The expression profile of other angiomiRs detected in the array and validated are shown in Fig.3A ,B. Of note, CD34-CD14+ PBMCs had also higher expression levels of potentially antiangiogenic miRs, such as miRs from the miR-17-92 cluster or miR-21 (Fig.3B ).
Pro-angiogenic capacity of CD34+ PBMCs is dependent on miR-126 expression
MiR-mimic-126 or anti-miR-126 treatment resulted in a markedly altered pro-angiogenic capacity of the CD34+, i.e. an enhanced tube formation was seen after miR-mimic-126 transfection into CD34+ cells, whereas a decreased tube formation was observed in response to anti-miR-126 transfected CD34+ cells (Fig.4A,B) . Similar results were observed when tube formation was examined in response to conditioned medium from CD34+ cells that were transfected with miR-mimic-126 or anti-miR-126, suggesting that the pro-angiogenic capacity of CD34+ cells is dependent on miR-126 and is largely mediated via paracrine factors (Fig.4C,D) .
CD34+ cells transfected with anti-miR-126 or miR-mimic-126 showed altered levels of miR-126,
i.e. reduced or increased miR-126 levels, respectively (Fig.4E ).
MiR-126 is secreted from CD34+ cells largely in microvesicles/exosomes and stimulates angiogenesis
MiR-126 levels were determined in supernatants from CD34+CD14+, CD34+CD14-, CD34-CD14+, CD34-CD14-MNC populations, and observed significantly higher secretion of miR-126
in supernatants of CD34+ cell populations. No significant difference was observed between the CD34+CD14+ and CD34+CD14-cell fractions ( Fig.2A,C) , whereas microvesicels and exosomes derived from miR-mimic-126 transfected cells had an enhanced effect on in-vivo angiogenesis (Suppl. Fig.2B,D) .
The transfer of secreted vesicles from CD34+ cells to the endothelial cells was assessed by adding the supernatants from PKH67 stained CD34+ cells. The vesicular fusion into endothelial cells resulted in acquisition of the color after overnight incubation. The majority of endothelial cells acquired the color as assessed by flow-cytometry analysis (Fig.5E) .
Blocking of the secretion of the vesicular particles by using GW4869 resulted in reduction of secreted miR-126 in the supernatant of the treated CD34+ cell and a subsequent increase of the miR in CD34+ cells (Fig.5F,G) . GW4869 is an inhibitor of neutral sphingomyelinase 2 that regulates ceramide synthesis which is crucial for triggering the secretion of membrane vesicles 25 Treatment of CD34+ cells with GW4869 lead to a loss of pro-angiogenic stimulation of the conditioned medium derived from these cells as compared to untreated CD34+ cells (Fig.5H) . Moreover, we have also examined the effects of different doses of the miR-mimic-126
or scrambled-miR on in-vivo angiogenesis. In these experiments, the higher doses of the miRmimic-126, but not of the scrambled-miR, had a more pronounced effect on in-vivo angiogenesis (Suppl. Fig.3B,C) .
High glucose treatment or diabetes leads to a loss of miR-126 expression and proangiogenic effects of CD34+ PBMCs that can be restored by miR-mimic-126 transfection
Exposure of CD34+ PBMCs to high-glucose substantially decreased their subsequent proangiogenic capacity as determined after washing of CD34+ PBMCs and subsequent coculture with HAECs, i.e. using an in-vitro tube formation assays (Fig.6A,B) . This loss of function was likely due to an alteration of secreted factors since decreased tube formation in HAECs was observed after treatment with the conditioned medium from high-glucose treated CD34+
PBMCs (Fig.6C,D) . Notably, expression of the pro-angiogenic miR-126 was down-regulated in high-glucose-treated CD34+ PBMCs as compared with buffer-treated cells in both, CD34+
CD34+ PBMCs and their supernatants (Fig.6E) . Of-note, CD34+ PBMCs derived from patients with type-2 diabetes had a substantially decreased miR-126 expression as compared with age and sex-matched healthy subjects (Fig.6F) .
Furthermore, CD34+ PBMCs exposed to high-glucose were transfected with miR-mimic-126 or scrambled miR and their capacity to promote endothelial tube formation was subsequently assessed. Notably, miR-mimic-126 treated high-glucose exposed CD34+ PBMCs showed a marked improvement in the promotion of tube formation (Fig.7A,B) .
Direct exposure of endothelial cells to miR-mimic-126 stimulates angiogenesis in-vitro and in-vivo
In addition, to determine whether miR-mimic-126 exposure of endothelial cells could directly impact angiogenesis, both in-vitro and in-vivo administration of miR-mimic-126 was examined.
Notably, as described above we have observed that miR-126 is released from CD34+ cells.
Moreover, CD34+ cell supernatants increased miR-126 levels in high-glucose-treated endothelial cells (Fig 7 C) . MiR-mimic-126 exposure, but not scrambled-miR administration to high-glucose-treated endothelial cells significantly increased their miR-126 levels (data not shown). Notably, addition of the miR-mimic-126 directly to the medium of high-glucose exposed HAECs increased tube formation as compared to addition of scrambled-miR (Fig.7D ) and downregulated PI3KR2, a known target of miR-126 in endothelial cells (Fig.7E) . Moreover, addition of miR-mimic-126, but not scrambled miR directly to the matrigel plug implanted in streptozotocininduced diabetic animals enhanced tube formation and increased hemoglobin content (as a sign of increased new vessel formation) in the matrigel plug as compared with scrambled miRtreated animals (Fig.7F,G) . These findings suggest that direct exposure of miR-mimic-126 can promote these angiogenic processes.
Discussion
In the present study we have observed a substantially higher expression of the angiomiR miR-126 in human CD34+ as compared to CD34-PBMC subsets. Notably, miR-126 was secreted by CD34+ PBMC subsets, largely in microvesicles and exosomes, and this secretion was altered by miR-mimic-126 or anti-miR-126 treatment. Modulation of miR-126 expression levels by either miR-mimic-126 or anti-miR-126 revealed that miR-126 is critical for the pro-angiogenic capacity of CD34+ PBMCs. In addition, we observed that reduced miR-126 expression is a novel mechanism leading to an impaired pro-angiogenic capacity in high-glucose-treated or diabetic patient-derived CD34+ PBMCs, which could be reversed by miR-mimic-126 treatment.
Previous studies have suggested that at least 2 morphologically and functionally distinct "endothelial progenitor cell" populations can be derived after culture from circulating mononuclear cells according to duration of culture and the baseline CD14 phenotypic marker expression 2, 28 . We have observed that the CD34+ fraction of cells showed a more potent proangiogenic effect in-vitro and in-vivo, however, we did not observe a significant difference between freshly isolated CD34+CD14+ and CD34+CD14-MNC-derived cell populations with respect to their pro-angiogenic capacity. Previous studies have demonstrated that monocytes can stimulate angiogenesis 2, 4, 28, 29 .
With the results of the present study one may speculate that the CD34+CD14+ MNC cell fraction may in particular contribute to such pro-angiogenic effects.
We have observed that the CD34+ CD14+ MNC fraction resulted in a significant promotion of tube formation, very similar to that observed in the CD34+ CD14-MNC fraction.
Notably, the present study for the first time demonstrates different angiomiR expression profiles in the PBMC sub-populations separated for their CD34+ and CD14+ surface expression. MiR-126 was substantially increased in both, the CD34+CD14+ and CD34+CD14-PBMC populations and was critical for the increased pro-angiogenic capacity of the CD34+ PBMC population. Previously, miR-126 has been suggested to play a critical role in vascular development 30, 31 . Moreover, following myocardial infarction miR-126 knockout mice showed impaired vascular growth in the infarct border zone 30, 31 . A reduced expression of potentially antiangiogenic miRs in CD34+ cells as compared to CD34-cells, such as miR-15a or miR-20a levels observed in the present study, may also support an increased pro-angiogenic capacity of CD34+ cells. However, given the observation that anti-miR-126 treated CD34+ cells had lost the capacity to stimulate angiogenesis, these differentially expressed miRs are likely not sufficient to explain the functional difference observed between CD34+ and CD34-MNC cell subsets.
Moreover, in the present study we have observed that the pro-angiogenic miR-126 is enriched in microvesicles and exosomes secreted by CD34+ progenitor cells and that these vesicles are suggested that miR-126 is released from endothelial apoptotic micro-particles and acts in a paracrine way 22 . These micro-particles were incorporated by surrounding endothelial cells, and miR-126 transfer has been proposed to increase production of CXCL12 in endothelial cells, promoting homing of progenitor cells after vascular injury.
In the present study we have observed that protein levels of phosphoinositol-3 kinase regulatory subunit 2 (PIK3R2), a known target of miR-126, are reduced in endothelial cells upon administration of miR-mimic-126, suggesting that the microRNA uptake regulates target expression in endothelial cells. PIK3R2 has been shown to inhibit pro-angiogenic signalling in endothelial cells by suppression of growth factor signalling via PI3 kinase pathways. 30, 31 Diabetes has been observed to lead to an impaired function of early endothelial progenitor cells 8, 9, 12 . In the present study we suggest a novel link between loss of pro-angiogenic Two other microRNAs that were found to be higher expressed in CD34+ cells as compared to CD34-mononuclear cells in the present study have very recently been suggested to be involved in the regulation of angiogenic processes in different endothelial cell types. We observed miR-100 expression to be higher in CD34+ as compared to CD34-mononuclear cells. MiR-100 expression in endothelial cells has been suggested to inhibit proliferation, tube formation, and sprouting activity and to act as an endogenous repressor of the serine/threonine protein kinase mammalian target of rapamycin 34 . This raises the possibility that this microRNA would rather limit the pro-angiogenic capacity of CD34+ mononuclear cells that needs, however, to be evaluated in future studies. MiR-10b was higher expressed in CD34+ as compared to CD34-mononuclear cells in the present study. MiR-10b has recently been suggested to regulate angiogenesis in human micro-vascular endothelial cells, where miR-10b over-expression promoted endothelial cell migration and tube formation 35 . These findings raise the possibility that this microRNA may also regulate pro-angiogenic effects in CD34+ mononuclear cells, that needs to be further evaluated in future studies. However, miR-10b was substantially higher expressed in CD34+CD14+ as compared to CD34+CD14-mononuclear cells, that had a rather similar pro-angiogenic capacity in the present study, that would suggest that miR-10b is not a major regulator of pro-angiogenic effects of CD34+ mononuclear cells. Vice versa, it is also possible that higher expression of potentially anti-angiogenic microRNA in CD34-mononuclear cells, such as from the miR-17-92 cluster or miR-21 as observed in the present study, may limit the pro-angiogenic capacity of CD34-mononuclear cells.
In summary, our present findings demonstrate a differential angiomiR expression in CD34+ and CD34-PBMC subpopulations. Increased angiomiR miR-126 expression in CD34+ PBMCs as compared to CD34-PBMCs was identified as a novel mechanism contributing to the increased capacity of these cells to promote angiogenic processes. Moreover, down-regulation of miR-126 in CD34+ PBMCs after high-glucose exposure or in diabetic patients represents a novel mechanism leading to an altered pro-angiogenic capacity in these conditions that can be rescued by miR-mimic-126 transfer. 
